Serotonin receptor 1A, Serotonin receptor 1B, and Serotonin receptor 1D (5-HT1A, 5-HT1B, 5-HT1D)

The serotonin receptor subtypes 5-HT1A, 5-HT1B, and 5-HT1D are G protein-coupled receptors (GPCRs) with seven transmembrane domains, primarily coupling to Gi/o proteins to inhibit adenylyl cyclase and regulate neurotransmitter release[1][3][5][7]. 5-HT1A receptors are found both pre- and post-synaptically in the central nervous system, where they modulate mood, anxiety, and cognition; 5-HT1B and 5-HT1D are distributed mainly presynaptically in serotonergic and non-serotonergic neurons, and in vascular tissues, where they contribute to neurotransmitter regulation, vascular tone, and migraine pathophysiology[2][3][4][7]. These receptors are important therapeutic targets in the treatment of depression, anxiety, migraine, and other neuropsychiatric and cardiovascular conditions. Drugs binding these receptors act primarily as agonists or antagonists, yielding therapeutic effects through modulation of serotonergic signaling. High homology among the 5-HT1 receptor family subtypes makes subtype-selective targeting challenging, a focus of ongoing drug discovery research[5]. Note: The provided name describes three distinct receptor subtypes frequently considered separately for structured pharmacological data.

Other names

5-hydroxytryptamine receptor 1A, 1B, 1DSerotonin receptor 1A, 1B, 1D5-HT1A, 5-HT1B, 5-HT1DHTR1A, HTR1B, HTR1D (gene symbols)

Agonism: Activation inhibits adenylyl cyclase via Gi/o proteins, resulting in decreased cAMP levels and inhibition of neurotransmitter release[1][3][7]. Antagonism/inverse agonism: Blockade leads to increased extracellular serotonin and altered neuronal activity (antipsychotic, antidepressant effect)[3][6]. Presynaptic autoreceptor inhibition: Elevates synaptic serotonin, potentiating SSRI effects[6].